Key terms

About DHR

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DHR news

Apr 08 9:46pm ET RBC Capital Reaffirms Their Buy Rating on Danaher (DHR) Apr 01 4:22pm ET Danaher files automatic mixed securities shelf Mar 27 3:36pm ET Danaher put volume heavy and directionally bearish Mar 25 2:05pm ET Ingersoll-Rand’s Dover deal not a threat to bioprocessing space, says KeyBanc Mar 15 9:39am ET China stimulus positive for GE HealthCare, tool companies, says Evercore ISI Feb 14 5:12pm ET Third Point buys McKesson, exits T-Mobile in Q4 Jan 31 9:46am ET Danaher price target raised to $282 from $254 at RBC Capital Jan 31 9:37am ET Danaher price target raised to $270 from $250 at Deutsche Bank Jan 31 9:17am ET Optimistic Outlook for Danaher: Buy Rating Affirmed Amid Recovery and Improved Target Price Jan 31 9:17am ET Danaher price target raised to $280 from $255 at Citi Jan 31 8:31am ET Danaher price target raised to $255 from $250 at Leerink Jan 31 8:20am ET Analysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Cencora (COR) Jan 31 7:33am ET Danaher price target raised to $280 from $265 at TD Cowen Jan 31 7:09am ET Danaher price target raised to $300 from $270 at JPMorgan Jan 31 7:05am ET Danaher price target raised to $259 from $252 at Baird Jan 31 5:31am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kura Oncology (KURA), HCA Healthcare (HCA) and Danaher (DHR) Jan 31 3:30am ET Wall Street Analysts Are Neutral on Top Healthcare Picks Jan 30 8:55pm ET Buy Rating Affirmed for Danaher with Increased Price Target Amid Strong Growth and Conservative Guidance Jan 30 6:10am ET Danaher sees FY24 revenue down low-single digits, consensus $24.05B Jan 30 6:07am ET Danaher sees Q1 revenue down high-single digits, consensus $5.73B Jan 30 6:04am ET Danaher reports Q4 adjusted EPS $2.09, consensus $1.89 Jan 29 8:25pm ET Notable companies reporting before tomorrow’s open Jan 29 12:50pm ET Notable companies reporting before tomorrow’s open Jan 26 8:45pm ET RBC Capital Keeps Their Buy Rating on Danaher (DHR) Jan 26 9:55am ET Early notable gainers among liquid option names on January 26th Jan 24 3:45pm ET Danaher call volume above normal and directionally bullish Jan 24 10:04am ET Netflix upgraded, Tesla initiated: Wall Street’s top analyst calls Jan 24 7:16am ET Danaher downgraded to Equal Weight on valuation at Barclays Jan 24 6:10am ET Danaher downgraded to Equal Weight from Overweight at Barclays Jan 11 1:30am ET Buy Rating Affirmed: Danaher’s Strong Q4 Performance and Market Leadership in Bioprocessing Jan 09 9:25am ET Danaher (NYSE:DHR) Drops on Dismal Q4 Outlook

No recent press releases are available for DHR

DHR Financials

1-year income & revenue

Key terms

DHR Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DHR Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms